R-Pharm hopes to dominate public procurements of anti-HIV and hepatitis drugs in Russia

22 November 2018

R-Pharm plans to dominate in public procurements of anti-HIV and hepatitis drugs in Russia, the overall annual value of which is estimated at 20 billion roubles (~$300 million), according to recent statements of some senior officials of the Russian Ministry of Health and sources of the company, The Pharma Letter’s local correspondent reports.

Several days ago the company completed registration of its anti-HIV drug under the Efavirenz-TL brand, and will probably put it up for state tenders already in 2019. It is planned the drug will be produced at the company’s plant in Khimki in the Moscow region.

In the meantime, R-Pharm is not the only Russian pharmaceutical company that will produce efavirenz, the active ingredient of Bristol-Myers Squibb's (NYSE: BMY) Sustiva. Currently analogues of the drug are produced by India’s Hetero Labs, as well as the local unit of US pharma giant Merck & Co (NYSE: MRK) and Russian firm Pharmsintez.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK